Neal Weinreb
5PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|May 13, 2023
The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158.Pramod K Mistry, Priya S Kishnani, Manisha Balwani
|Sep 03, 2022
Physiologically-Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug-Drug Interactions.Siddhee A Sahasrabudhe, Shen Cheng, Mahmoud Al-Kofahi
|Apr 14, 2018
MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association.Neal J Weinreb, Pramod K Mistry, Barry E Rosenbloom
|Jun 02, 2017
Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.Pramod K Mistry, Julie L Batista, Hans C Andersson
Pageof 1
